Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
Chill Yee MD
Chill C. Yee MD Advisory Board
See All Experts
featured
Published in Primary Care

Journal Scan / Research · November 14, 2019

Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

JAMA: The Journal of the American Medical Association

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Jonathan Temte MD, PhD

JAMA: The Journal of the American Medical Association
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
JAMA 2019 Sep 27;[EPub Ahead of Print], E Alexander, L Goldberg, AF Das, GJ Moran, C Sandrock, LB Gasink, P Spera, C Sweeney, S Paukner, WW Wicha, SP Gelone, J Schranz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated